Yatharth hospital & Trauma Care Services Limited has announced a scheduled visit for investors and analysts to its newly operationalised hospitals in New Delhi and Faridabad. The company made this disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on March 16, 2026.

Visit Details

The investor and analyst visit is scheduled for Friday, March 20, 2026, covering the company's facilities in New Delhi and Faridabad. The primary objective is to provide participants with a comprehensive understanding of the company's operations and facilities at these locations.

Regulatory Compliance

The company has ensured full compliance with regulatory requirements for this investor engagement. Company Secretary & Compliance Officer Ritesh Mishra signed the disclosure, emphasizing that no unpublished price sensitive information will be shared during the visit.

Hospital Network

Yatharth Hospital operates an extensive network of healthcare facilities across multiple locations. The company's hospitals are strategically located in:

• Greater Noida (Sector Omega-01 and Sector-01 Greater Noida West)
• Noida (Sector-110)
• Faridabad (Sector-88 and Plot No. 9 & 9A, Sector 20B)
• New Delhi (4C Institutional Area, North Extension, Model Town 3)
• Orchha, Madhya Pradesh (Jhansi Mauranipur Highway)

Corporate Information

The disclosure was made through official communication to both National Stock Exchange of India Limited and BSE Limited. The company maintains its registered office in New Delhi and corporate office in Noida, with comprehensive investor information available on its official website at yatharthhospitals.com.

Yatharth Hospital & Trauma Care Services Limited has announced exceptional Q3FY26 quarterly results for the quarter ended December 31, 2025, showcasing industry-leading financial performance with record revenue growth. The healthcare provider delivered outstanding consolidated results with revenue from operations reaching ₹3,205 million compared to ₹2,192 million in the corresponding quarter of the previous year, representing substantial growth of 46%.

Outstanding Financial Performance

The company demonstrated remarkable financial metrics across all key parameters during Q3FY26. Consolidated profit after tax reached ₹431 million, marking a significant 41% increase from ₹305 million in Q3FY25. The company's EBITDA stood at a record ₹742 million, up 35% year-on-year, while maintaining healthy margins despite expansion activities.

Strategic Expansion Driving Growth

The company's growth momentum was significantly driven by newly operational hospitals, with New Delhi and Faridabad Sec-20 contributing ₹279 million in revenue, representing 9% of the Group's revenues within their first full quarter of operations. These new facilities demonstrated strong performance with 100% of revenues derived from cash and TPA patients, reflecting the company's strategic focus on improving payer mix from day one of operations.

Nine-Month Performance and Operational Excellence

For the nine-month period ended December 31, 2025, the company maintained consistent growth with consolidated revenue reaching ₹8,577 million compared to ₹6,487 million in the corresponding previous period, representing 32% growth. The Group ARPOB witnessed continued momentum at ₹33,744, up 10% year-on-year, with Noida Extension recording its highest-ever ARPOB at ₹44,000, up 16% year-on-year.

Earnings Conference Call and Recording Availability

Following the announcement of Q3FY26 results on February 5, 2026, the management hosted a conference call on February 6, 2026, at 1:00 PM IST to discuss the performance and answer questions from participants. The company has now made the audio recording of the earnings call available on its website for stakeholder access and transparency.

Regulatory Compliance and Transparency

In compliance with SEBI regulations 30 and 47, the company published its Q3FY26 unaudited financial results in leading newspapers on February 6, 2026. The results were published in Financial Express (English) and Jansatta (Hindi) to ensure transparency and accessibility for all stakeholders. The complete financial results and earnings call recording are available on the company's website.

Management Commentary and Future Outlook

Commenting on the performance, Mr. Yatharth Tyagi, Whole Time Director, highlighted the company's ability to successfully acquire, integrate, and scale new assets rapidly. He emphasized that the Agra facility, integrated from February 2026, is expected to contribute meaningfully from the current quarter. The Greater Faridabad hospital has turned profitable and is now adding significantly to Group financials, reflecting strong execution and clinical excellence.